Genetic targeting of XBP1 or pharmacological inhibition of IRE1α kinase activity using KIRA8 led to reduced cholesterol levels and MDSC abundance, resulting in activation of effective anti-tumor immunity in mouse cancer models [196]. The gene discussed is XBP1; the disease is neoplasm.